Subscribe To
Zevia pbc (zvia) q3 2022 earnings call transcript
Zevia PBC (NYSE:ZVIA ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Reed Anderson - Investor Relations Amy Taylo...
November 13, 2022, 12:16 pm
Lifestance health group, inc. (lfst) q3 2022 earnings call transcript
LifeStance Health Group, Inc. (NASDAQ:LFST ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Monica Prokocki - Vice ...
November 13, 2022, 12:15 pm
Amylyx pharmaceuticals, inc. (amlx) q3 2022 earnings call transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lindsey Allen - Head of...
November 13, 2022, 9:10 am
Acutus medical, inc. (afib) q3 2022 earnings call transcript
Acutus Medical, Inc. (NASDAQ:AFIB ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Rela...
November 13, 2022, 8:50 am
Ryan specialty holdings, inc. (ryan) q3 2022 earnings call transcript
Ryan Specialty Holdings, Inc. (NYSE:RYAN ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Noah Angeletti – Head-...
November 13, 2022, 4:52 am
Vitru limited (vtru) q3 2022 earnings call transcript
Vitru Limited (NASDAQ:VTRU ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Carlos Freitas – Chief Financial Off...
November 13, 2022, 3:33 am
Cerevel therapeutics holdings, inc. (cere) q3 2022 earnings call transcript
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Matt Calistri - V...
November 13, 2022, 12:43 am
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm